Export growth rate hit a five-year high | 2017 China's pharmaceutical foreign trade surrender beautiful answer sheet

2017 Top 30 list of China's pharmaceutical and healthcare products exporters

Pharmaceutical Network February 27 hearing recently held in China's pharmaceutical foreign trade conference, China Pharmaceutical Health products The Import and Export Chamber of Commerce (hereinafter referred to as 'Medicare Chamber of Commerce') released the data on China's pharmaceutical exports in 2017. Overall, the demand for international pharmaceutical market increased in 2017. The structural reform on the supply side of our country has achieved initial success and new momentum of development is taking shape , China Pharmaceutical is forming a unique differentiated competitive advantage in the international market. The export of pharmaceutical products shows a trend of increasing prices and increasing steadily. "Meng Dongping, vice president of the Healthcare Business Association, said.

Statistics show that in 2017, the successful export of Chinese medicine and health products reversed the decline of the previous year with the export value increasing by 9.44% to 60.799 billion U.S. dollars, the largest increase in nearly five years.

In 2017, the export value of Chinese medicine products was 3.64 billion U.S. dollars, an increase of 2.07% over the same period of last year. The performance of key products in the export of Chinese medicine products has been differentiated: the exports to the ASEAN, the United States and the European Union maintained their growth with an increase of 17% and 9% 5%; exports to Japan increased slightly; exports to traditional markets such as Korea and Hong Kong dropped by 12.4% and 9.8% respectively. In particular, the breakdown of plant extracts showed a gradual increase in the export of plant extracts Export of Chinese herbal medicines and Pieces has not yet out of the negative growth downturn, exports fell 2.23%, due to the Southeast Asian market Demand continued to slump.

The export performance of western medicine products picked up obviously with the export volume of 35.456 billion U.S. dollars, up 12.62% over the same period of last year, of which the export volume of APIs was 29.117 billion U.S. dollars, up 13.71% over the same period of last year. The export of APIs to major markets such as the United States, EU and India An increase of 23.8%, 9.8% and 13.5% respectively.

'Premium pharmaceutical companies in the international market share and bargaining power is gradually improving the average export price of 25 bulk raw materials rose 11%, which is the main reason for stimulating the export growth of bulk drugs.' Meng Dongping explained that by the environmental protection The cost of raw materials increased, the upstream supply shortages, raw material prices and other objective factors, the backward production capacity of APIs industry gradually withdraws, the industry concentration continues to improve.And raw material exports began to change from 'take the amount' to 'quality', the export price rising, last year In the first half of the year, the export volume of APIs showed a trend of price increase and volume increase. In the second half of this year, the export volume gradually picked up.

It is noteworthy that the export of western medicine preparations in 2017 reached 3.456 billion U.S. dollars, up 8.32% over the same period of last year.China's formulated products showed strong growth in exports to the EU, North America and other regulated markets, with an increase of 53.5% over the same period of the previous year. Innovative pharmaceutical companies Local pharmaceutical companies such as Hengrui Pharmaceutical and Qilu Pharmaceutical have succeeded in establishing themselves in the European and American markets and starting to make a difference. "The local pharmaceutical companies can gain a foothold in the international mainstream markets such as Europe and the United States, which is not only conducive to the export of pharmaceutical products in China, Also let people see the development momentum of China's pharmaceutical. 'Meng Dongping stressed.

In 2017, the way of international participation in the pharmaceutical industry in our country presents the following four major new features:

First, the processing trade of pharmaceutical products increased sharply, and in 2017, the export value of the processing trade of medical products in China reached 10.431 billion U.S. dollars, up 6.11% over the same period of last year, of which the processing trade of pharmaceutical products increased by a large margin, up by 48.80 percent. 'China's tax- Attracting many foreign merchants to choose this way to cooperate with Chinese pharmaceutical companies, overseas orders increased rapidly.This also indirectly shows that China's pharmaceutical production equipment in the production, quality management, technical level and other hardware and software to achieve an overall increase.Meng Dongping said.

The increase in overseas orders brought to the pharmaceutical companies in our country not only the growth of profits, but also our understanding of each other's strict quality control system in the process of foundry for foreign companies. This laid the foundation for our own products to open the door to the international market Quality Basis. "Xinhua Pharmaceutical Co., Ltd. Shandong Xin Xuejie, deputy general manager admitted.

Second, the participation of Chinese pharmaceutical enterprises in diversified forms of international division of labor and the gradual emergence of medical service trade out of the country.With the extension of the pharmaceutical industry chain and industry segmentation, CRO (Pharmaceutical R & D Contract Outsourcing), CSO (Pharmaceutical Sales Contract Outsourcing), etc. Emerging formats gradually rise in our country.Especially CRO, has undertaken a large number of foreign pharmaceutical research and development and clinical trials, become an integral part of the international pharmaceutical industry chain.

In recent years, the rapid expansion of the scale of foreign service trade of Chinese medicine has become a new bright spot in the pharmaceutical foreign trade of our country. The data shows that about 2,000 Chinese medicine clinicians are dispatched annually in our country, accounting for 60% of the total number of medical service personnel dispatched. Chinese medicine service trade institutions in more than 20 countries and regions started a Chinese medicine hospital , Chinese medicine clinics, Chinese medicine health care institutions, the annual consultation volume reached 250,000 people. Chinese medicine foreign service trade has also led to sales of Chinese medicine products overseas. According to China Beijing Tong Ren Tang (Group) Co., Ltd. Deputy Director of Foreign Economic Relations Office Director Du Xin introduced Tong Ren Tang has 140 overseas layout pharmacy , Clinics and Chinese medicine health centers, the medical services provided by them have led to the increase of the sales volume of traditional Chinese medicine products and realized the goal of "taking medicine with doctors."

Third, the transaction volume of overseas mergers and acquisitions hit record highs In early 2017, Sanchai Group invested 819 million U.S. dollars to acquire Dendreon, a U.S. biopharmaceutical company, setting a record for Chinese pharmaceutical companies to acquire the first overseas biopharmaceutical company. In July of the same year, Fosun Pharma To 1.091 billion US dollars acquisition of Indian pharmaceutical company Gland Pharma Limited, Chinese pharmaceutical companies overseas mergers and acquisitions investment record once again be refreshed.

Fourthly, R & D achievements will be transformed into harvesting and high value-added products will go out and accelerate In 2017, Chinese pharmaceutical companies received ANDA's 34 new product applications, which are 1.7 times the number approved in the previous year. The more pharmaceutical companies began to enter the US generic drug market.In addition, Baekje Shenzhou, Hengrui medicine, reputation Heng Pharmaceutical, Nanjing Legend enterprise Of the six products, with the form of licensing and overseas R & D giant, multinational investment bank to cooperate with the total amount of more than 3.2 billion U.S. dollars.

With the expansion of export of medical and health care products, the trade friction experienced by Chinese pharmaceutical enterprises has also increased significantly.According to the data from the Medical and Business Chamber of Commerce, a total of 15 trade friction investigations have been encountered in the export of pharmaceutical products in China in 2017, doubling the number of the previous year and involving Cases of intellectual property increased significantly.

Specifically, India has the largest number of trade friction investigations launched against pharmaceutical products in China, including five anti-dumping investigations and one anti-circumvention investigation. In the United States, most of the investigations initiated were in the name of IPR infringement, including the investigation of 337 IPR infringement cases 'And one case of antitrust litigation; the EU, Ukraine also launched a number of anti-dumping investigations.

'Encountered the investigation are all traditional and superior products of our country, mainly antipyretic and analgesic products, the advantages of raw materials and anti-cancer agents.' Meng Dongping said in her view, the reason for the trade friction in China's pharmaceutical products Because the strong growth momentum of China's pharmaceutical industry keeps competitors nervous. 'In international trade, when the market competitiveness and market share of a certain product significantly increase, the market space for similar products will be squeezed, thereby causing trade friction Investigation.China's pharmaceutical industry to speed up the process of internationalization, trade frictions will also face more and more. 'Health Insurance Chamber of Commerce vice president of Law Beibei this situation is called' out of the sea 'Chinese pharmaceutical companies encountered the' growth troubles '-' The industry has become stronger, there will be such trouble '.

Data released by the health care providers show that China medicine The international competitiveness of the industry is gradually strengthened.Not only the 34 products of the United States have obtained the American ANDA code in 2017, but also many products of Hengrui and Yaosheng obtained the IND (Clinical Research Approval) In the biopharmaceutical R & D for the pharmaceutical industry in the future, China has the second largest biopharmaceutical population in the world after the United States.

Zhang Beipei put forward her own proposal on how to deal with the frequent trade frictions of Chinese pharmaceutical enterprises, and at present, China has formed a four-body linkage mechanism that includes government departments, industry organizations, enterprises and lawyers to help trade enterprises cope with trade Friction, but the key is that pharmaceutical companies should strive to enhance their ability to change passive defense as the initiative to defend their legitimate rights and interests.In Zhang Beibei view, many foreign pharmaceutical companies provoke trade friction is not intended to win the lawsuit, but Try to fight for a period of time, disrupt the pace of Chinese pharmaceutical enterprises to enter the overseas market.Therefore, Chinese pharmaceutical companies should correctly view the investigation of trade friction, and actively safeguard their own rights and interests.

It is gratifying to note that in recent years, awareness of IPR protection in China's pharmaceutical enterprises and their ability to defend their legal rights have risen significantly. In 2017, two patent litigation won the victories: In June, Huahai Pharmaceutical patent challenge on paroxetine capsules In December, Green Leaf Pharmaceutical won a rival case of rivastigmine single-dose patches in Germany.